Capsule Summary Slides

Share

Program Content

Activities

  • RELATIVITY-047 2-Yr Update
    RELATIVITY-047: 2-Yr Update of First-line Nivolumab + Relatlimab vs Nivolumab in Advanced Melanoma
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 08, 2023

  • Fianlimab/Cemiplimab in Adv Melanoma
    Phase I Trial of Fianlimab (Anti‒LAG-3 mAb) + Cemiplimab (Anti‒PD-1 mAb) in Patients With Advanced Melanoma
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 08, 2023

  • Adjuvant mRNA-4157 + Pembro in Melanoma
    Phase II KEYNOTE-942: DMFS With Adjuvant mRNA-4157 (V940) + Pembrolizumab vs Pembrolizumab in Resected High-Risk Melanoma
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 08, 2023

  • CheckMate 76K: Biomarker Analysis
    Biomarker Analysis From CheckMate 76K Phase III Trial of Adjuvant Nivolumab vs Placebo in High-Risk Stage IIB/C Melanoma
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 09, 2023

  • OpACIN-neo and PRADO
    OpACIN-neo and PRADO: Effect of Response-Directed Treatment Personalization on Survival After Neoadjuvant Immune Checkpoint Blockade in Stage III Melanoma
    Capsule Summary
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 09, 2023

  • KEYNOTE-716: DMFS and RFS Update
    Phase III KEYNOTE-716 Update: Final DMFS Analysis of Adjuvant Pembrolizumab vs Placebo in Stage IIB/IIC Melanoma
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 12, 2023

Provided by

ProCE Banner

Supporters

Supported by educational grants from Merck Sharp & Dohme Corp. and Regeneron Pharmaceuticals, Inc.

Merck Sharp & Dohme Corp.

Regeneron Pharmaceuticals, Inc